#IBD #Pancreatitis #UlcerativeColitis
#CrohnsDisease
Chronic inflammatory bowel diseases (IBD),
which include
ulcerative colitis (UC) and
Crohn’s disease (CD), are autoimmune
conditions marked by persistent intestinal inflammation with often
unpredictable progression. Beyond digestive symptoms, they are known for their
systemic nature, frequently causing
extraintestinal manifestations that affect
the skin, joints, eyes, and liver.
Among these systemic complications,
pancreatic
involvement remains
relatively unexplored. Some clinical studies have reported
an
increased incidence of pancreatitis — either acute (AP) or chronic (CP) — in
patients with IBD. However, this association is still poorly defined due to
numerous
confounding factors, such as the use of
thiopurines,
corticosteroids,
or the presence of
metabolic comorbidities (alcohol use, smoking,
dyslipidemia). It remains unclear whether this link reflects a
true
inflammatory comorbidity or is merely a
side effect of treatment.
To clarify this potential connection, the
present study was initiated to assess whether there is a
causal relationship
independent of environmental factors. The objective was to determine whether
IBD — UC and CD —
genetically increases the risk of pancreatitis, and whether
the reverse association is also valid.
IBD: a hidden factor in pancreatitis?
In this study, more than
31,000 patients with
IBD (13,768 with ulcerative colitis and 17,897 with Crohn’s disease) were
selected and compared to
over 850,000 control individuals regarding
pancreatitis risk.
The findings demonstrate that IBD significantly increases the risk of both
acute and chronic pancreatitis. Moreover, ulcerative colitis is associated with
a higher risk of both AP and CP, with overrepresentation observed in two
independent data sets. In contrast, Crohn’s disease is linked only to an
increased risk of AP, with no significant impact on CP.
Notably, reverse analysis suggests that
acute
pancreatitis may exert a protective effect against the development of IBD,
particularly Crohn’s disease. This speculative result paves the way for new
pathophysiological hypotheses regarding
bidirectional interactions between the
pancreatic and intestinal axes.
These findings were supported by
sensitivity
analyses, including tests for horizontal pleiotropy, leave-one-out analyses,
and MR-Egger regression, which revealed neither major bias nor significant
heterogeneity.
Read next: Should surgery be broader?
An inflammatory link to monitor
Inflammatory bowel diseases are autoimmune
intestinal disorders with systemic implications. Among their potential
extra-digestive complications,
pancreatic involvement remains poorly
characterized both epidemiologically and pathophysiologically. One of the major
challenges is to determine whether pancreatitis, whether acute or chronic,
constitutes an
intrinsic comorbidity of IBD or merely reflects treatment side
effects or other confounding factors. The complexity of this link — often clouded by
exposure to immunosuppressants, genetic variation, and comorbidities —
complicates the interpretation of observational data.
This study aimed to
clarify the nature of the
relationship between IBD and pancreatitis by eliminating common biases through
a
bidirectional Mendelian randomization analysis. The results provide, for the
first time,
robust genetic evidence of a causal relationship between IBD and
pancreatitis, particularly in its acute form. They confirm that UC is
associated with an increased risk of both
acute and chronic pancreatitis, while
CD appears to be linked only to acute pancreatitis.
Further research is needed to
better understand
shared inflammatory mechanisms, especially IL-1 and IL-33 cytokine pathways,
and to
assess the impact of immunosuppressive treatments on pancreatic risk.
These findings could lead to the
integration of pancreatic screening into the
clinical follow-up of IBD patients, particularly those with UC, to better
prevent extra-colonic digestive complications.
Read next: IBD: a double burden
